Safety of insulin eye drops in the treatment of open angle glaucoma: a randomized phase I clinical trial.

In 30 seconds

This phase I randomized controlled trial evaluated the safety and tolerability of topical insulin eye drops at concentrations of 100 and 500 units/mL in patients with open-angle glaucoma. Eighteen participants were treated for 5 days, with follow-up assessments. The study found no serious adverse events related to insulin, indicating good short-term tolerability.

Key findings

• No serious adverse events related to insulin were observed during the trial.
• One participant experienced a transient near-hypoglycemia event at 3.9 mmol/L.
• Ocular symptoms were limited to mild burning sensations upon application.

Why it matters

The findings suggest that topical insulin may be a safe option for patients with open-angle glaucoma, addressing the need for neuroprotective therapies. Understanding the safety profile is crucial for future studies exploring its efficacy.